Slide 1: Investor Webinar Presentation
Holista Colltech Limited (ASX:HCT / ABN 24 094 515 992) 283 Rokeby Road Subiaco WA 6008 P: +61 412 474 180 W: www.holistaco.com For personal use only Investor Webinar Presentation ASX Announcement 04 August 2022 Holista Colltech Limited (ASX: HCT, “Holista” or “the Company”) is pleased to announce i
Slide 2: For further information, please contact
For further information, please contact: Our Investor Mailing list: investors@holistaco.com General Enquiries: enquiries@holistaco.com Australia Malaysia For personal use only 283 Rokeby Road Subiaco 12th Floor, Amcorp Trade Centre, PJ WA 6008 Western Australia Tower No. 18, Persiaran Barat off Jala
Slide 3: Webinar Presentation August 2022
For personal use only Webinar Presentation August 2022 Passion to combine economic success with enriching lives for a sustainable future
Slide 4: Disclaimer
Disclaimer For personal use only This document has been prepared by Holista Colltech Limited and comprises written material/slides for a presentation concerning Holista Colltech Limited and its subsidiaries. The presentation is for information purposes only and does not constitute or form part of an
Slide 5: Encouraging Finish to 2021
Encouraging Finish to 2021 Momentum carrying through into current year For personal use only Holista Colltech is an emerging Australian developer of health Record 2021 Revenue** Continued Momentum and wellness products in the Strong rebound with growth Sales receipts in 1QFY22 and US$4.4 trillion Gl
Slide 6: Year of Achievements
Year of Achievements Foundations for a stronger 2022 For personal use only Positive First COVID test commercial for All- Increasing order from Natural orders for GI Launch of Country Nano Silver LiteTM and new Farms/ Disinfectant Successful 80LessTM from products: Starbucks Orders for tests showing
Slide 7: Strong Finish to 1H2022
Strong Finish to 1H2022 Record sales receipts in 2Q 2022 For personal use only $k Growth in Quarterly Cash Receipts Latest Quarter 1-year ago 3,000 2,789 June quarter sales receipts of $2.8m (+55.4% pcp) 2,500 2,427 broke 1Q22 record high 2,000 2,074 1,922 1,814 1,795 1,665 Op Cash Flow improved sig
Slide 8: Building on FY21 Results
Building on FY21 Results Revenue & margin growth For personal use only Full Year Performance: V-shaped FY21 revenue goes up 13% to record $8m recovery following COVID impacted FY20 $8.2 51.4% Millions $8.0 51.2% $7.8 51.0% Net loss before tax narrowed to $1.2m from $5.6m (2020) $7.6 50.8% $7.4 50.6%
Slide 9: Dietary Supplements
Dietary Supplements Developments & updates For personal use only Largest division contributing 77% of FY21 group revenue The Group markets and sells thirty-seven (37) different propriety supplements and owns leading vitamin Growing faster than market with 2Q22 sales up >38% pcp to brands in Malaysia
Slide 10: Healthy Food Ingredients
Healthy Food Ingredients Developments & updates For personal use only Ongoing orders from key customers like US bread supplier Holista developed the Costanzo’s and Asian beverage maker Rex Industries clean-label low GI premix called GI LiteTM for healthy breads, noodles and pasta, as well as healthy
Slide 11: Infection Control
Infection Control Developments & updates For personal use only Launch of all-natural Super Bio Nano Silver that kills 99.99% of human coronavirus strain* Holista offers a range of natural and alcohol-free sanitising solutions that have been effective against viruses, including COVID-19 Focusing on o
Slide 12: Ovine Collagen
Ovine Collagen Developments & updates For personal use only Holista is the only Company Current sales primarily to cosmetic manufacturer Behn Meyer producing Australian-made sheep collagen that is extracted using a patented process. Its product is culturally acceptable, fully Chinese State-Owned Ent
Slide 13: Positive Outlook
Positive Outlook Improved 2022 results expected For personal use only Rebound in 2021 results with Growth drivers from new momentum persisting into products and global partnerships current year Expanding margins with cost Forecast 1H22 revenue growth of control and change in sales mix ~26% to $4.5m
Slide 14: Board of Directors & Advisors
Board of Directors & Advisors Expertise to lead the group forward For personal use only Rajen Manicka Walter Joseph Loren King Jay Stephenson Roscoe Moore Chairman & CEO Non-Executive Director Non-Executive Director Company Secretary Advisor Dr Manicka spent nine Successful track record Worked in co
Slide 15: Thank You
For personal use only To join our mailing list please email: update@holistaco.com Thank You For further information, please contact: Corporate Matters: investor@holistaco.com General Enquiries: enquiries@holistaco.com Investor/Media Relations: Brendon Lau (m: 0409 341 613, e: brendon@vantagepointpar